8-K: Century Therapeutics Presents Promising Interim Results for CNTY-101 in Lymphoma Trial

Century Therapeutics announced encouraging interim results from its Phase 1 ELiPSE-1 study of CNTY-101, showing a manageable safety profile and preliminary efficacy in relapsed or refractory non-Hodgkin lymphoma.

Summary

• Century Therapeutics presented interim results from the Phase 1 ELiPSE-1 study of CNTY-101 at the ASCO 2024 Annual Meeting.
• CNTY-101 is an investigational allogeneic, iPSC-derived natural killer cell therapy with six precision gene edits.
• The study is evaluating CNTY-101 in patients with relapsed or refractory non-Hodgkin lymphoma.
• Interim results show a manageable safety profile with no dose-limiting toxicities or graft-versus-host disease observed.
• Preliminary efficacy data shows a 30% complete response rate and a 40% objective response rate across all evaluable patients.
• In the five patients treated with higher doses, the complete response rate was 40% and the objective response rate was 60%.
• A novel cell-free DNA method indicates that CNTY-101 persists outside the bloodstream.
• The study is ongoing with dose escalation at higher levels.
• The company is also planning to initiate a Phase 1 trial for CNTY-101 in systemic lupus erythematosus in the first half of 2024.

Sentiment

Score: 8

Explanation: The document presents positive interim clinical data, a strong cash position, and a clear strategic direction, indicating a favorable outlook for the company.

Positives

• CNTY-101 has shown a favorable safety profile in the ongoing Phase 1 trial.
• The therapy has demonstrated encouraging early efficacy signals, including complete and partial responses.
• The novel cell-free DNA method provides a way to monitor the persistence of CNTY-101.
• The company's Allo-Evasion technology allows for repeat dosing without the need for continued lymphodepletion.
• The company is expanding its pipeline into autoimmune diseases, with a Phase 1 trial in SLE planned for the first half of 2024.
• The company has a strong cash position extending into 2026.

Negatives

• The study is still in the dose escalation phase, and further data is needed to confirm the efficacy and safety of CNTY-101.
• The results are preliminary and based on a small number of patients.
• Some patients experienced Grade 1 and 2 cytokine release syndrome (CRS) and one patient experienced Grade 1 immune effector cell-associated neurotoxicity syndrome (ICANS), although these resolved quickly.

Risks

• The success of CNTY-101 is crucial for the company's future.
• Clinical trial results may not be predictive of final outcomes.
• Regulatory approvals are not guaranteed.
• The company relies on key collaborative relationships for manufacturing and development.
• There are risks associated with commercializing the product and developing sales and marketing capabilities.
• The company faces risks related to geopolitical issues, banking instability, and inflation.

Future Outlook

The company plans to complete dose escalation in the ELiPSE-1 study and move into dose expansion. They also intend to initiate a Phase 1 trial for CNTY-101 in systemic lupus erythematosus in the first half of 2024 and expect initial data by year-end 2024. The company is also pursuing additional regulatory filings in other prioritized autoimmune disease indications.

Management Comments

• Adrienne Farid, PhD, Chief Operations Officer and Head of Early Development, stated that the interim results support the potential of CNTY-101, showing additional responses across escalating doses and different types of B-cell malignancies.
• Adrienne Farid also noted the encouraging safety profile at higher doses, achieved by leveraging their proprietary Allo-Evasion technology.

Industry Context

This announcement is significant in the context of the broader cell therapy field, where allogeneic therapies are being developed to overcome the limitations of autologous therapies. The use of iPSC-derived cells and Allo-Evasion technology positions Century Therapeutics as a leader in next-generation cell therapies.

Comparison to Industry Standards

• The complete response rate of 30% and objective response rate of 40% in heavily pretreated R/R NHL patients is competitive with other cell therapies in this space, such as CAR-T therapies.
• The ability to administer multiple doses without lymphodepletion, enabled by Allo-Evasion technology, is a key differentiator compared to many existing cell therapies.
• The use of iPSC-derived cells for manufacturing offers a potential advantage in terms of scalability and cost compared to donor-derived or autologous cell therapies.
• Companies like Kite Pharma and Novartis have established CAR-T therapies for lymphoma, but Century's approach with iPSC-derived NK cells and Allo-Evasion technology represents a novel approach.
• The planned expansion into autoimmune diseases, specifically SLE, is a strategic move to broaden the application of their technology, similar to other companies exploring cell therapies for autoimmune conditions.

Stakeholder Impact

• Shareholders: The positive clinical data and strong cash position are likely to be viewed favorably by investors.
• Patients: The potential for a new treatment option for relapsed or refractory non-Hodgkin lymphoma and systemic lupus erythematosus is a positive development.
• Employees: The company's progress and expansion into new areas may provide opportunities for growth and development.
• Partners: The company's progress may strengthen existing collaborations and attract new partnerships.

Next Steps

• Complete dose escalation in the ELiPSE-1 study.
• Progress into dose expansion in the ELiPSE-1 study.
• Initiate the Phase 1 CALiPSO-1 trial in SLE in the first half of 2024.
• Pursue additional autoimmune health authority filing submissions for CNTY-101 in the second half of 2024.

Key Dates

Keywords

CNTY-101, iPSC, cell therapy, allogeneic, natural killer cells, non-Hodgkin lymphoma, Allo-Evasion, systemic lupus erythematosus, immuno-oncology, autoimmune disease